Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease - PubMed (original) (raw)
Review
. 2018 Jan;67(1):123-133.
doi: 10.1002/hep.29466. Epub 2017 Dec 1.
Affiliations
- PMID: 28802062
- PMCID: PMC5767767
- DOI: 10.1002/hep.29466
Review
Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease
Chris Estes et al. Hepatology. 2018 Jan.
Abstract
Nonalcoholic fatty liver disease (NAFLD) and resulting nonalcoholic steatohepatitis (NASH) are highly prevalent in the United States, where they are a growing cause of cirrhosis and hepatocellular carcinoma (HCC) and increasingly an indicator for liver transplantation. A Markov model was used to forecast NAFLD disease progression. Incidence of NAFLD was based on historical and projected changes in adult prevalence of obesity and type 2 diabetes mellitus (DM). Assumptions were derived from published literature where available and validated using national surveillance data for incidence of NAFLD-related HCC. Projected changes in NAFLD-related cirrhosis, advanced liver disease, and liver-related mortality were quantified through 2030. Prevalent NAFLD cases are forecasted to increase 21%, from 83.1 million (2015) to 100.9 million (2030), while prevalent NASH cases will increase 63% from 16.52 million to 27.00 million cases. Overall NAFLD prevalence among the adult population (aged ≥15 years) is projected at 33.5% in 2030, and the median age of the NAFLD population will increase from 50 to 55 years during 2015-2030. In 2015, approximately 20% of NAFLD cases were classified as NASH, increasing to 27% by 2030, a reflection of both disease progression and an aging population. Incidence of decompensated cirrhosis will increase 168% to 105,430 cases by 2030, while incidence of HCC will increase by 137% to 12,240 cases. Liver deaths will increase 178% to an estimated 78,300 deaths in 2030. During 2015-2030, there are projected to be nearly 800,000 excess liver deaths.
Conclusion: With continued high rates of adult obesity and DM along with an aging population, NAFLD-related liver disease and mortality will increase in the United States. Strategies to slow the growth of NAFLD cases and therapeutic options are necessary to mitigate disease burden. (Hepatology 2018;67:123-133).
© 2017 The Authors. Hepatology published by Wiley Periodicals, Inc., on behalf of the American Association for the Study of Liver Diseases.
Figures
Figure 1
NAFLD Markov Model.
Figure 2
Adjusted prevalence of NAFLD by age group and sex (mean ± 95% confidence interval).
Figure 3
Distribution of the NAFLD and NASH population by fibrosis stage in the United States for 2015 and 2030. (A) NAFLD; (B) NASH.
Figure 4
Prevalent NAFLD, NAFL, and NASH cases in the United States, 2015‐2030.
Figure 5
Incident decompensated cirrhosis, HCC, and liver‐related deaths among the prevalent NAFLD population in the United States, 2015‐2030.
Similar articles
- Nonalcoholic fatty liver disease burden - Saudi Arabia and United Arab Emirates, 2017-2030.
Alswat K, Aljumah AA, Sanai FM, Abaalkhail F, Alghamdi M, Al Hamoudi WK, Al Khathlan A, Al Quraishi H, Al Rifai A, Al Zaabi M, Babatin MA, Estes C, Hashim A, Razavi H. Alswat K, et al. Saudi J Gastroenterol. 2018 Jul-Aug;24(4):211-219. doi: 10.4103/sjg.SJG_122_18. Saudi J Gastroenterol. 2018. PMID: 29956688 Free PMC article. - Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.
Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, Caballeria J, Colombo M, Craxi A, Crespo J, Day CP, Eguchi Y, Geier A, Kondili LA, Kroy DC, Lazarus JV, Loomba R, Manns MP, Marchesini G, Nakajima A, Negro F, Petta S, Ratziu V, Romero-Gomez M, Sanyal A, Schattenberg JM, Tacke F, Tanaka J, Trautwein C, Wei L, Zeuzem S, Razavi H. Estes C, et al. J Hepatol. 2018 Oct;69(4):896-904. doi: 10.1016/j.jhep.2018.05.036. Epub 2018 Jun 8. J Hepatol. 2018. PMID: 29886156 - The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe.
Younossi ZM, Blissett D, Blissett R, Henry L, Stepanova M, Younossi Y, Racila A, Hunt S, Beckerman R. Younossi ZM, et al. Hepatology. 2016 Nov;64(5):1577-1586. doi: 10.1002/hep.28785. Epub 2016 Sep 26. Hepatology. 2016. PMID: 27543837 - Clinical epidemiology and disease burden of nonalcoholic fatty liver disease.
Perumpail BJ, Khan MA, Yoo ER, Cholankeril G, Kim D, Ahmed A. Perumpail BJ, et al. World J Gastroenterol. 2017 Dec 21;23(47):8263-8276. doi: 10.3748/wjg.v23.i47.8263. World J Gastroenterol. 2017. PMID: 29307986 Free PMC article. Review. - Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y, Fukusato T. Takahashi Y, et al. World J Gastroenterol. 2014 Nov 14;20(42):15539-48. doi: 10.3748/wjg.v20.i42.15539. World J Gastroenterol. 2014. PMID: 25400438 Free PMC article. Review.
Cited by
- The multifaceted roles of B lymphocytes in metabolic dysfunction-associated steatotic liver disease.
Li H, Xia N. Li H, et al. Front Immunol. 2024 Sep 20;15:1447391. doi: 10.3389/fimmu.2024.1447391. eCollection 2024. Front Immunol. 2024. PMID: 39372417 Free PMC article. Review. - Progress in the Study of Animal Models of Metabolic Dysfunction-Associated Steatotic Liver Disease.
Fu Y, Hua Y, Alam N, Liu E. Fu Y, et al. Nutrients. 2024 Sep 15;16(18):3120. doi: 10.3390/nu16183120. Nutrients. 2024. PMID: 39339720 Free PMC article. Review. - The Predictive Value of Time-Varying Noninvasive Scores on Long-Term Prognosis of NAFLD in South Korea.
Chung SW, Park MK, Zhang X, Wang T, Jemielita T, Fernandes G, Engel SS, Jang H, Lee YB, Cho EJ, Lee JH, Yu SJ, Yoon JH, Kim YJ. Chung SW, et al. Can J Gastroenterol Hepatol. 2024 Sep 16;2024:5667986. doi: 10.1155/2024/5667986. eCollection 2024. Can J Gastroenterol Hepatol. 2024. PMID: 39314528 Free PMC article. - A clinical decision support tool for metabolic dysfunction-associated steatohepatitis in real-world clinical settings: a mixed-method implementation research study protocol.
Fishman J, Alexander T, Kim Y, Kindt I, Mendez P. Fishman J, et al. J Comp Eff Res. 2024 Oct;13(10):e240085. doi: 10.57264/cer-2024-0085. Epub 2024 Sep 20. J Comp Eff Res. 2024. PMID: 39301878 Free PMC article. - Correlation between ratio of fasting blood glucose to high density lipoprotein cholesterol in serum and non-alcoholic fatty liver disease in American adults: a population based analysis.
Jin X, Xu J, Weng X. Jin X, et al. Front Med (Lausanne). 2024 Sep 4;11:1428593. doi: 10.3389/fmed.2024.1428593. eCollection 2024. Front Med (Lausanne). 2024. PMID: 39296907 Free PMC article.
References
- Younossi ZM, Otgonsuren M, Henry L, Venkatesan C, Mishra A, Erario M, et al. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology 2015;62:1723‐1730. - PubMed
- Sanyal A, Poklepovic A, Moyneur E, Barghout V. Population‐based risk factors and resource utilization for HCC: US perspective. Curr Med Res Opin 2010;26:2183‐2191. - PubMed
- Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 2013;10:686‐690. - PubMed
- Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al.; American Gastroenterological Association; American Association for the Study of Liver Diseases; American College of Gastroenterology . The diagnosis and management of non‐alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012;142:1592‐1609. - PubMed
- Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007;45:846‐854. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical